Dostarlimab in the Treatment of Endometrial Cancer: An Overview

Introduction: Endometrial cancer, the most frequent gynaecological malignancy in developed countries, is rising and has few modern therapies. Dostarlimab may treat MMRdeficient (dMMR) and MSI-H tumours. Methods: GARNET and RUBY clinical trial data were evaluated for ORR, PFS, and safety. Also, pembrolizumab and other immunotherapeutics were compared. Results: Dostarlimab inhibits PD-1, activating T cells and anti-tumour immunity. RUBY observed increased tiredness, diarrhoea, and nausea, and improved PFS in dMMR/MSI-H endometrial cancer patients, whereas GARNET reported a 43.5% ORR. Dostarlimab works as well as pembrolizumab for certain patients. Biomarker-driven immunotherapy has potential for CRC and NSCLC. Discussion: Here, dostarlimab's promising PD-1 inhibitor efficacy in endometrial cancer therapy with dMMR/MSI-H tumours is reviewed. Immunogenic tumours activate T-cells via PD-1 targeting. In dMMR/MSI-H patients, GARNET showed a 43.5% objective response rate, whereas RUBY improved progression-free survival with dostarlimab and chemotherapy. Dostarlimab and PD-1 inhibitors induce tiredness, diarrhoea, and nausea. Treatment may be isolated or combined for long-term therapy. Studies suggest that dostarlimab outperforms pembrolizumab. Though encouraging, larger populations and additional tumour types require further investigation. A successful dostarlimab study requires biomarkers and randomized controlled trials. Conclusion: Dostarlimab is a highly effective immunotherapeutic option for endometrial cancer, particularly in dMMR/MSI-H cases. Its favourable efficacy and safety profile make it a key agent in personalized cancer treatment, with ongoing trials expanding its clinical applications.